Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LAE102 · 1 trial · 2 indications
Number of participants with SAEs \- Evaluation of Safety and Tolerability of LAE102
Number of participants with TEAEs \- Evaluation of Safety and Tolerability of LAE102
| Arm | Type | Description |
|---|---|---|
| LAE102 SC | EXPERIMENTAL | Participants will receive a single dose by SC administration (3 dose levels) |
| Placebo SC | PLACEBO_COMPARATOR | Participants will receive a single dose by SC administration |
| LAE102 IV | EXPERIMENTAL | Participants will receive a single IV dose (1 dose level) |
| Placebo IV | PLACEBO_COMPARATOR | Participants will receive a single IV dose |
| Name | Type | Description |
|---|---|---|
| LAE102 SC | DRUG | A single dose of LAE102 will be administered subcutaneously |
| Placebo SC | DRUG | A single dose of placebo administered subcutaneously |
| LAE102 IV | DRUG | A single dose of LAE102 administered intravenously |
| Placebo IV | DRUG | A single dose of placebo administered intravenously |
Inclusion Criteria: * Females aged 45 to 75 years of age inclusive, at time of signing the informed consent. * Are healthy postmenopausal female participants. * Have a body mass index (BMI) within the range 20.0 - 32.0kg/m\^2 inclusive at screening. * Have follicle stimulating hormones (FSH) levels...
LAE102 is an investigational small molecule being studied for use in postmenopausal women. It is being evaluated in healthy adult female participants to assess its safety, tolerability, and pharmacokinetics. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
LAE102 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research on this investigational small molecule for postmenopausal women.
LAE102 is in Phase 1 clinical development. A Phase 1 study has been completed, which investigated the safety, tolerability, and pharmacokinetics of the drug in postmenopausal women. The drug remains investigational and has not received regulatory approval.
LAE102 has one completed clinical trial, identified as NCT06908707. This Phase 1 study, titled "A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women," enrolled 32 healthy female participants aged 45 years and older in the United States.
LAE102 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A completed Phase 1 trial has evaluated its safety and tolerability, but the drug has not yet received marketing authorization from the FDA or any other regulatory body.